Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
BL

NASDAQ · BLLN

BillionToOne, Inc.

Healthcare · Medical - Diagnostics & Research

$113.32

Down-$1.52 (-1.32%)

Updated Nov 1, 2026, 12:06 AM

SID Score

6.4/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.42B
P/E ratio
-142.14
Dividend yield
0.00%
52-week range
$61.96 – $150.44
Volume
468.31K
Avg. volume
256.93K

Price performance · BLLN

BLLN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

BLLN closed at $113.32 after 21 trading sessions, up 7.01% for the selected period.

Last close
$113.32
Period change
+7.01%
Period low
$93.07
Period high
$114.84
Daily close
View OHLC price history
BLLN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$113.29$114.02$110.42$113.32468.31K
Oct 29, 2026$114.02$115.20$112.67$114.84583.18K
Oct 28, 2026$113.96$119.20$113.11$114.00453.43K
Oct 27, 2026$111.84$115.92$110.05$114.07372.36K
Oct 26, 2026$108.00$111.58$106.285$111.465404.78K
Oct 23, 2026$106.11$108.99$102.8901$107.77482.39K
Oct 22, 2026$104.34$105.97$102.00$105.68377.83K
Oct 21, 2026$103.27$107.04$102.80$104.67377.59K
Oct 20, 2026$101.12$104.67$99.55$103.50398.67K
Oct 19, 2026$98.95$102.50$98.234$101.03462.78K
Oct 16, 2026$101.41$102.57$96.21$98.12605.95K
Oct 15, 2026$97.18$102.93$93.441$102.73427.23K
Oct 14, 2026$93.375$99.75$93.375$97.88424.93K
Oct 13, 2026$91.81$96.00$90.48$94.44664.22K
Oct 12, 2026$97.61$97.61$91.22$93.07491.52K
Oct 9, 2026$94.46$100.31$94.46$98.09325.04K
Oct 8, 2026$94.06$96.015$91.01$95.41386.3K
Oct 7, 2026$99.42$99.85$94.52$95.75679.89K
Oct 6, 2026$107.86$112.8699$98.90$99.941.12M
Oct 5, 2026$105.15$110.09$104.42$109.06407.8K
Oct 2, 2026$106.39$109.38$102.91$105.90418.3K

Latest BLLN news

The latest Smart Investors Daily articles mentioning BLLN.

Stock researchCompany · Overview

BLLN research

Overview

Company profile and research snapshot.

Company profile

BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$136.40
Implied upside
—
Analysts
—
BLLN recent ratings
DateFirmRatingTarget
Oct 1, 2026GuggenheimBuy—
Sep 2, 2026Canaccord GenuityBuy—
Aug 6, 2026JP MorganOverweight—
Aug 6, 2026BTIGBuy—
Jun 29, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 14, 2026

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Ea

Yahoo · Oct 7, 2026

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar ResponseMENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced the publication of the first peer-reviewed head-to-head study comparing Northstar Response®, a tissue-free,

Yahoo · Oct 3, 2026

BillionToOne (NasdaqGS:BLLN) Stock Fair Value Edges Higher As Analysts Weigh Tech And Reimbursement Risk

BillionToOne’s updated analyst narrative now centers on a fresh Fair Value price target of US$128.57, compared with the prior US$122.14 level in this framework. Recent Street research links this adjustment to enthusiasm around the company’s technology and market reach, while also reflecting new questions on reimbursement risk and long term pricing power. As you read on, you will see how these moving pieces shape the evolving story around BillionToOne and what to watch as the narrative changes...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By